Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
NetSceinttific notes 'steady progress' by portfolio company PDS
10:36am, Thursday, 31'st Mar 2022
NetScientific PLC (AIM:NSCI) says its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB) (Nasdaq: PDSB), made good progress through 2021, hitting a number of milestones. Ilian Iliev, NetSc
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
07:30pm, Tuesday, 22'nd Mar 2022
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vac
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results
01:00pm, Wednesday, 09'th Mar 2022 GlobeNewswire
FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, today announced the Company will release financial results for the three- and twelve-month periods ended December 31, 2021, on Wednesday, March 23, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
11:52pm, Monday, 21'st Feb 2022
PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2021 Results - Earnings Call Transcript
12:26pm, Wednesday, 10'th Nov 2021
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2021 Results - Earnings Call Transcript
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
08:30am, Wednesday, 27'th Oct 2021
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
04:30pm, Wednesday, 13'th Oct 2021
FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's prop
No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
08:30am, Wednesday, 15'th Sep 2021
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's pro
Best Penny Stocks To Buy In 2021? 5 That Turned $2,500 Into $26,000
04:02pm, Monday, 13'th Sep 2021
Were these penny stocks on your list this year? The post Best Penny Stocks To Buy In 2021?
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
08:30am, Monday, 13'th Sep 2021
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's pro
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
08:30am, Tuesday, 07'th Sep 2021
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's pro
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2021 Results - Earnings Call Transcript
12:49pm, Thursday, 12'th Aug 2021
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2021 Results - Earnings Call Transcript
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
07:05am, Thursday, 12'th Aug 2021
FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's prop
New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fidu
